This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
4D Pharma shares cancelled from trading on London's AIM AN
4D pharma Cancels Trading on London's AIM MT
TRADING UPDATES: GCP Infra hails NAV rise; Jadestone profits from oil AN
4D pharma plc Updates Results from Renal Cell Carcinoma Cohort CI
UK shareholder meetings calendar - next 7 days AN
4D Pharma seeks approval for equity fundraise to lift suspension AN
4D pharma's Blautix Phase II Clinical Trial Results Published in Alimentary Pharmacology & Therapeutics CI
4D Pharma says trial results show Blautix eases IBS symptoms AN
4D pharma Remains Suspended from Trading on London's AIM MT
4D Pharma plc Announces Delay in Publication of Interim Results for the Six Months to 30 June 2022 CI
4D pharma plc Announces Publication of Preclinical Research Showing Live Biotherapeutic MRx0006 Efficacy in Animal Model of Autism Spectrum Disorder CI
4D pharma plc(NasdaqGM:LBPS) dropped from NASDAQ Composite Index CI
4D Pharma plc Is Temporarily Pausing Recruitment into Ongoing Clinical Trials CI
4D Pharma Temporarily Halts Patient Enrollment In Clinical Trials For Cancer, Asthma, Parkinson's Disease Drugs MT
4D Pharma Says Nasdaq to Delist Shares from Exchange MT
4D Pharma Receives Notice Of Delisting From Nasdaq MT
Chardan Capital Downgrades 4D pharma to Neutral from Buy on Likelihood of Share Dilution MT
Chardan Capital Downgrades 4D pharma to Neutral from Buy MT
Ladenburg Thalmann Downgrades 4D Pharma to Neutral From Buy MT
Top Premarket Decliners MT
4D pharma Plans Phase 2 Trial for Metastatic Urothelial Carcinoma Maintenance Therapy MT
4D pharma Presents Trial in Progress Poster on Study of MRx0518 in Combination with BAVENCIO® in Patients with Unresectable Locally Advanced or Metastatic Urothelial Carcinoma at the 2022 American Society of Clinical Oncology Annual Meeting CI
European ADRs Move Higher in Tuesday Trading MT
4D pharma plc Reports Earnings Results for the Full Year Ended December 31, 2021 CI
4D pharma plc Auditor Raises 'Going Concern' Doubt CI
Chart 4D pharma plc
More charts
4D pharma plc is a United Kingdom-based pharmaceutical company. The Company is focused on developing Live Biotherapeutic Products (LBPs), a class of drugs derived from the human gut microbiome. The Company's LBPs are biologics based on live organisms, namely single strains of bacteria. It has developed MicroRx, its LBP discovery platform. MicroRx interrogates its library of bacterial isolates for therapeutic functionality and characterizes the bacterial isolates using a range of complementary tools and technologies. Its microbiome profiling platform, MicroDx, analyses the microbiome to aid the diagnosis and treatment of patients with its Live Biotherapeutics. Its MicroRx platform has generated a pipeline of development programs in therapeutic areas, including immuno-oncology, gastrointestinal (GI), respiratory, autoimmune and central nervous system (CNS) diseases. Its MicroRx enables the discovery of MRx-4DP0004, which is engaged in an ongoing Phase I/II with partly controlled asthma.
More about the company
  1. Stock Market
  2. Equities
  3. DDDD Stock
  4. News 4D pharma plc
  5. 4D Pharma Temporarily Halts Patient Enrollment In Clinical Trials For Cancer, Asthma, Parkinson's Disease Drugs